Nephrol Dial Transplant Vol. 19 No. 11 © ERA-EDTA 2004; all rights reserved
Editorial Review
Renal cysts and diabetes syndrome resulting from mutations in hepatocyte nuclear factor-1ß
1 Exeter Kidney Unit, Royal Devon and Exeter Hospital (Wonford) and 2 Diabetes and Vascular Medicine, Peninsula Medical School, Exeter, UK
Correspondence and offprint requests to: Dr Coralie Bingham, Exeter Kidney Unit, Royal Devon and Exeter Hospital (Wonford), Barrack Road, Exeter, Devon EX2 5DW, UK. Email: C.Bingham@exeter.ac.uk
Keywords: diabetes; hepatocyte nuclear factor-1ß; renal cysts; transcription factors
| The first 150 words of the full text of this article appear below. |
Introduction
Mutations in the gene encoding the transcription factor hepatocyte nuclear factor (HNF)-1ß have recently been described in association with a variety of abnormalities of renal development. The most consistent clinical feature is the presence of renal cysts and most affected subjects also have early-onset diabetes. The association of renal cysts and diabetes with an HNF-1ß mutation is termed the renal cysts and diabetes (RCAD) syndrome [1–3]. As more families have been described with HNF-1ß mutations it has become apparent that there are additional phenotypic features in some subjects, including genital tract malformations [4–6], hyperuricaemia, young-onset gout [7], deranged liver function tests [8] and pancreatic atrophy [9]. Mutations in the HNF-1ß gene may, therefore, be considered to cause a multisystem disorder. This article reviews the background to the discovery of HNF-1ß mutations as a cause of renal disease, describes the variable
HNF-1ß mutations: the connection with maturity-onset diabetes of the young
The HNF-1ß renal phenotype
The HNF-1ß diabetic phenotype
Non-renal features of HNF-1ß mutations
Genital tract malformations
Hyperuricaemia and gout
Abnormal liver function tests
Developmental abnormalities and other rare features
HNF-1ß expression during embryonic development
Molecular genetics of HNF-1ß mutations
Functional studies on HNF-1ß mutations
Disease mechanisms in man
Conclusions
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. J. Murray, K. Thomas, C. J. Mulgrew, S. Ellard, E. L. Edghill, and C. Bingham Whole gene deletion of the hepatocyte nuclear factor-1{beta} gene in a patient with the prune-belly syndrome Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2412 - 2415. [Full Text] [PDF]
|
|
|
|
 |
|
 R. I. Dmitrieva, C. A. Hinojos, E. Boerwinkle, M. C. Braun, M. Fornage, and P. A. Doris Hepatocyte Nuclear Factor 1 and Hypertensive Nephropathy Hypertension, June 1, 2008; 51(6): 1583 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Edghill, R. A. Oram, M. Owens, K. L. Stals, L. W. Harries, A. T. Hattersley, S. Ellard, and C. Bingham Hepatocyte nuclear factor-1{beta} gene deletions--a common cause of renal disease Nephrol. Dial. Transplant., February 1, 2008; 23(2): 627 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Carette, C. Vaury, A. Barthelemy, S. Clauin, J.-P. Grunfeld, J. Timsit, and C. Bellanne-Chantelot Exonic Duplication of the Hepatocyte Nuclear Factor-1{beta} Gene (Transcription Factor 2, Hepatic) as a Cause of Maturity Onset Diabetes of the Young Type 5 J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2844 - 2847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kitanaka, U. Sato, and T. Igarashi Regulation of human insulin, IGF-I, and multidrug resistance protein 2 promoter activity by hepatocyte nuclear factor (HNF)-1{beta} and HNF-1{alpha} and the abnormality of HNF-1{beta} mutants J. Endocrinol., January 1, 2007; 192(1): 141 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J Welters, S. Senkel, L. Klein-Hitpass, S. Erdmann, H. Thomas, L. W Harries, E. R Pearson, C. Bingham, A. T Hattersley, G. U Ryffel, et al. Conditional expression of hepatocyte nuclear factor-1{beta}, the maturity-onset diabetes of the young-5 gene product, influences the viability and functional competence of pancreatic {beta}-cells. J. Endocrinol., July 1, 2006; 190(1): 171 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Hattersley and E. R. Pearson Minireview: Pharmacogenetics and Beyond: The Interaction of Therapeutic Response, {beta}-Cell Physiology, and Genetics in Diabetes Endocrinology, June 1, 2006; 147(6): 2657 - 2663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Hattersley and F. M. Ashcroft Activating Mutations in Kir6.2 and Neonatal Diabetes: New Clinical Syndromes, New Scientific Insights, and New Therapy Diabetes, September 1, 2005; 54(9): 2503 - 2513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Gloyn, F. Reimann, C. Girard, E. L. Edghill, P. Proks, E. R. Pearson, I. K. Temple, D. J.G. Mackay, J. P.H. Shield, D. Freedenberg, et al. Relapsing diabetes can result from moderately activating mutations in KCNJ11 Hum. Mol. Genet., April 1, 2005; 14(7): 925 - 934. [Abstract] [Full Text] [PDF]
|
|